Since the 1980s, the prevalence of obesity has almost doubled worldwide. Treatments for
obesity include lifestyle modification, medications and surgery. Newer anti-obesity …

More than 40 years after publication of the U niversity G roup D iabetes P rogram trial, the
cardiovascular safety of sulphonylureas is still contentious. Although several hypotheses …

As an example of iatrogenic diabetes, we discuss the problem of diabetes mellitus in
patients receiving atypical antipsychotics. The risk of diabetes mellitus appears to be …

In Kohortenstudien wurden eine erhöhte Prävalenz depressiver Störungen bei diabetischen
Patienten gezeigt. Trotz zahlreicher Untersuchungen sind die zugrundeliegenden …

Über 160.000 Personen waren an den analysierten Studien beteiligt gewesen, mehr als
96% davon waren an Typ-2-Diabetes erkrankt. Im Laufe des medianen Follow-up von 2, 2 …

The aim of any lipid-lowering drug should not be merely to correct a biochemical
abnormality. It should be to prevent the clinical consequences of that abnormality. It is …

Comments on a study by P. Bjorntorp and colleagues on the role of the brain in
degenerative metabolic disease. Propositions for the role of neuroendocrine pathways in the …

In addition to readily controllable short-term side effects, highly active antiretroviral therapy
(HAART) also has long-term side effects: lipodystrophy syndrome, hyperlipoproteinemia …

Weight gain is associated with the use of many psychotropic medications, including
antidepressants, mood stabilizers, antipsychotic drugs, and may have serious long term …

Aims To determine whether adiposity modified the effect on the cardiovascular safety of
sulphonylureas as a first‐line therapy compared with metformin among patients with type 2 …